RxDoctor Payments Data

J Gimbel, MD

Clinical Cardiac Electrophysiology · Fort Wayne, INNPI 1932199627

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (30.3%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 47.1% of the total. Reporting peaked in 2019 at $10,194 and has fallen 86.0% since, to $1,431 in 2025.

$25,080in general payments, 2019–2025

Across 219 payments — averaging $114.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
  • Medtronic$6K
  • Abbott$4K
  • Boston Scientific$927
  • Biosense Webster, Inc.$643
  • Johnson & Johnson$453
  • plus $1K from 16 others

What the payments were for

  • Consulting fees$2,97512%
  • Speaking & faculty fees$7,20029%
  • Travel & lodging$7,30629%
  • Food & beverage$7,59930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,080 in reported general payments places this provider in the 60th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$175,880
Medicare patients
546
Services billed
2,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban355$407,468
XareltoRivaroxaban139$147,989
JardianceEmpagliflozin35$48,383
EntrestoSacubitril/Valsartan29$44,472
FarxigaDapagliflozin Propanediol12$8,555
Flecainide Acetate69$3,425
Colchicine54$3,114
Mexiletine Hcl26$2,901
Dofetilide39$2,870
Diltiazem 24hr Er (Cd)Diltiazem Hcl64$2,826
Metoprolol Succinate187$2,209
SotalolSotalol Hcl30$895
Amiodarone Hcl42$680
Carvedilol74$586
Spironolactone83$496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$201$407,468355 claims
Johnson & JohnsonXarelto$453$147,989139 claims
Boehringer IngelheimJardiance$32$48,38335 claims
NovartisEntresto$182$44,47229 claims
AstraZenecaFarxiga$139$8,55512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →